Cannabinoid Type 1Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa

JadersonV.Ferreira,[a] Gisele A. Chaves,[a] BiancaL.B.Marino,[a] Kessia P. A. Sousa,[a] Lucilene R. Souza,[a] Maiara F. B. Brito,[a] Hueldem R. C. Teixeira,[a] CarlosH.T.P.daSilva,[b] Cleydson B. R. Santos,[c] and Lorane I. S. Hage-Melim*[a]

Introduction

Drug addictions are an ongoing problem for society,affecting around27million people worldwide.[1] Amongthe main drugs used is Cannabis sativa,with about 20%ofglobalyouthusing it illicitly.[2] This plant biosynthesizes over 600 compounds, including more than 60 differentcannabinoids,[3] which are now recognized for both their toxicity and potential therapeutic effects.[4] The main component responsible for the psychoactive effects of C. sativa is D9-tetrahydrocannabinol (D9-THC).[5] Other components include cannabinol (CBN), carboxylated THC, cannabivarin, tetrahydrocannabivarin, and D8-THC, as well as the most abundantcannabinoids such as cannabigerol (CBG),cannabichromene (CBC), and cannabidiol (CBD). The latterconstitutes roughly40% of the active substances produced by the plant (Figure 1).[6]…

Deixe uma resposta